Arbutus Biopharma Corporation

DB:I9DN Stock Report

Market Cap: €638.7m

Arbutus Biopharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mike McElhaugh

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage29.8%
CEO tenure2yrs
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mike McElhaugh's remuneration changed compared to Arbutus Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$77m

Mar 31 2024n/an/a

-US$74m

Dec 31 2023US$2mUS$483k

-US$73m

Sep 30 2023n/an/a

-US$75m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$1mUS$449k

-US$69m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021n/an/a

-US$88m

Sep 30 2021n/an/a

-US$87m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$1mUS$415k

-US$76m

Compensation vs Market: Mike's total compensation ($USD1.62M) is about average for companies of similar size in the German market ($USD1.46M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.

CEO

Mike McElhaugh (50 yo)

2yrs

Tenure

US$1,620,485

Compensation

Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...

Leadership Team

NamePositionTenureCompensationOwnership
Michael McElhaugh
Co-Founder2yrsUS$1.62mno data
Michael Sofia
Chief Scientific Officer9.8yrsUS$1.61m0.79%
€ 5.0m
David Hastings
CFO & Chief Accounting Officer6.4yrsUS$1.46m0.0088%
€ 56.4k
Lisa Caperelli
Vice President of Investor Relations3.2yrsno datano data
J. Naftzger
General Counsel1.3yrsno datano data
Shannon Briscoe
Vice President of Human Resourcesno datano datano data
Karen Sims
Chief Medical Officer1.3yrsno data0.0028%
€ 17.8k
R. Mackay-Dunn
Corporate Secretary14.5yrsno datano data

3.2yrs

Average Tenure

60yo

Average Age

Experienced Management: I9DN's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael McElhaugh
Co-Founderless than a yearUS$1.62mno data
Richard Henriques
Independent Non-Executive Director9.9yrsUS$174.24k0.00053%
€ 3.4k
Daniel Burgess
Independent Director7.7yrsUS$161.74k0%
€ 0
Keith Manchester
Independent Non-Executive Director9.7yrsUS$156.74k0.024%
€ 155.3k
Adrian Di Bisceglie
Member of Scientific Advisory Boardno datano datano data
Charles Rice
Member of Scientific Advisory Boardno datano datano data
James Meyers
Independent Director6.1yrsUS$176.74k0%
€ 0
William Symonds
Chairman of Scientific Advisory Board6.1yrsno datano data
Frank Torti
Independent Chairman of the Board of Directors6yrsUS$187.99k0%
€ 0
Fabien Zoulim
Member of Scientific Advisory Boardno datano datano data
Scott Biller
Member of Scientific Advisory Boardno datano datano data
Ulrike Protzer
Member of Scientific Advisory Boardno datano datano data

6.1yrs

Average Tenure

57.5yo

Average Age

Experienced Board: I9DN's board of directors are considered experienced (6.1 years average tenure).